What is Citigroup's price target for MRTX?

Citigroup's latest stated price target for Mirati Therapeutics Inc. (MRTX) is $48, from its action on Aug 10, 2023.

What is Citigroup's rating on MRTX?

Citigroup rates MRTX Buy, a bullish rating, as of Aug 10, 2023.

When did Citigroup last change its view on MRTX?

On Aug 10, 2023, Citigroup upgrades to Buy from Neutral, price target $51 to $48.

Citigroup MRTX price target and rating history

Mirati Therapeutics Inc. (MRTX) · Health Care

Citigroup rates Mirati Therapeutics Inc. (MRTX) Buy with a $48 price target, as of its latest action on Aug 10, 2023. It has published 3 rating actions on MRTX since March 2022, including 1 upgrade and 1 downgrade.

Current rating: Buy
Price target: $48
Median target, all firms: Too few
Actions on MRTX: 3

Citigroup price target on MRTX

Citigroup price target on MRTX, each point a stated target, March 2022 to August 2023.

Every Citigroup rating on MRTX

Aug 10, 2023
UpgradeCitigroup upgrades to Buy from Neutral, price target $51 to $48
Dec 9, 2022
DowngradeCitigroup downgrades to Neutral from Buy, price target $121 to $53
Mar 2, 2022
ReiterateCitigroup cuts its price target to $227 from $244, keeps Buy

Questions about Citigroup and MRTX

What is Citigroup's price target for MRTX?: Citigroup's latest stated price target for Mirati Therapeutics Inc. (MRTX) is $48, from its action on Aug 10, 2023.
What is Citigroup's rating on MRTX?: Citigroup rates MRTX Buy, a bullish rating, as of Aug 10, 2023.
When did Citigroup last change its view on MRTX?: On Aug 10, 2023, Citigroup upgrades to Buy from Neutral, price target $51 to $48.

More MRTX rating histories

All Citigroup ratings MRTX news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.